Company Overview
argenx is the Belgian immunology company behind Vyvgart, one of the most commercially successful rare disease drug launches of the past decade. Vyvgart — and its subcutaneous formulation Vyvgart Hytrulo — works by reducing the abnormal antibodies that drive a class of severe autoimmune diseases, targeting a mechanism called FcRn. It is currently approved for myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, and has become the standard of care in both indications with striking speed. Most retail investors have never heard of argenx. Most institutional healthcare investors consider it one of the most important biotech stories of the decade.
Yesterday, BofA Securities raised its price target on argenx to $1,088, calling it a top pick for 2026 heading into a catalyst-rich second half of the year, with BofA considering immune-mediated necrotizing myopathy a key entry point into rheumatology that could expand the Vyvgart franchise significantly. Eight analysts have recently revised their earnings estimates upward. BofA’s target is not even the most bullish on the Street — Wells Fargo carries a $1,291 price target with an Overweight rating, Stifel sits at $1,255 Buy, TD Cowen at $1,146 Buy, and Guggenheim at $1,135 Buy. The stock trades in the mid-$800s — a wide gap to every major target on the Street, driven by a single near-term uncertainty: whether the Phase 3 ALKIVIA myositis trial data expected this quarter delivers.
Key Technical and Fundamental Drivers
Yesterday’s BofA Target Raise → $1,088, Top Pick Heading Into H2 2026
BofA Securities raised its price target on argenx to $1,088 on July 1, 2026, reiterating its Buy rating and naming argenx a top pick for the second half of the year as myositis data approaches. H.C. Wainwright maintained a Buy rating and $940 price target, RBC Capital reiterated Outperform at $890, TD Cowen upheld Buy at $1,146, and Oppenheimer maintained Outperform at $1,014 — a cluster of coordinated analyst reiterations across the past week that signals broad institutional conviction ahead of Q3 catalysts.
63% Vyvgart Revenue Growth → $1.3 Billion in a Single Quarter
The Vyvgart franchise reported approximately $1.3 billion in global net sales for Q1 2026, marking a 63% year-over-year increase. This is the commercial machine that underpins the entire argenx story — a drug generating over $5 billion in annualized sales, growing at triple-digit-adjacent rates, with a recently expanded FDA label covering all adult myasthenia gravis patients that significantly broadens its addressable market. A recent FDA label expansion to all adult gMG patients solidifies Vyvgart’s dominant position in the autoimmune sector and removes an overhang that had limited commercial penetration in certain patient subgroups.
Phase 3 ALKIVIA Myositis Data → Q3 2026 Binary Catalyst
The Phase 3 ALKIVIA trial topline data in myositis is expected in the third quarter of 2026, representing the most significant near-term binary event in argenx’s pipeline. Autoimmune myositis, particularly immune-mediated necrotizing myopathy and dermatomyositis, are prioritized for label expansion based on strong biology, urgent unmet need, and robust Phase 2 data. IMNM and DM are seen as multi-blockbuster opportunities, supporting long-term growth and leadership in immunology. The interim data from the ALKIVIA+ extension study presented at EULAR 2026 in June indicated sustained, clinically meaningful improvement and durable safety in patients with autoimmune myositis, with no new safety signals — a constructive read-through for the pivotal Phase 3 data coming this quarter.
Vision 2030 → New CEO, 2.5x Patient Growth Target
Newly appointed CEO Karen Massey reaffirmed “Vision 2030,” targeting 2.5x more patients on Vyvgart and five molecules in late-stage development by the end of the decade. argenx’s pipeline extends well beyond Vyvgart’s current indications: four Phase 3 readouts are expected in 2026 alone — for ocular myasthenia gravis, myositis, multifocal motor neuropathy, and immune thrombocytopenia — alongside early-stage pipeline updates that could provide additional upside. A company with a $5 billion-plus annualized drug franchise and four additional Phase 3 catalysts arriving in a single year is operating at a pace that most biotechs reach only once per decade.
July 23 Earnings → Three Weeks Away, Q2 Commercial Momentum in Focus
argenx reports Q2 2026 earnings on July 23, three weeks from today. The print will deliver the first full quarter of commercial data following the FDA’s label expansion to all adult gMG patients — the key metric analysts will watch is whether the expanded label is driving accelerated new patient starts beyond the extraordinary Q1 trajectory. Q2 will also be the last quarterly report before Phase 3 ALKIVIA data is expected, making it the final opportunity to establish a commercial baseline heading into what could be a transformative binary event.
Market Takeaway
argenx’s investment case in July 2026 is built on two parallel tracks that reinforce each other. The first is the commercial engine: a drug generating over $5 billion in annualized revenue, growing at 63% year-over-year, with a recently expanded label and a new CEO committed to 2.5x patient growth by 2030. The second is the pipeline catalyst: Phase 3 ALKIVIA myositis data arriving this quarter that, if positive, would open a multi-billion-dollar new market and validate the FcRn mechanism across an entirely new disease category. The gap between the stock’s mid-$800s trading range and analyst consensus targets of $940 to $1,291 reflects the uncertainty around that binary event — not skepticism about the core business.
The risks are genuine and worth naming directly. Biotech binary events are the market’s most unforgiving setup when they disappoint — a Phase 3 failure in myositis would be a significant negative catalyst regardless of the underlying gMG commercial strength. The decision to separate the ALKIVIA trial analysis into IMNM and dermatomyositis cohorts while discontinuing the polymyositis arm — disclosed at a recent analyst meeting — introduces additional complexity around how the FDA will interpret the data package and what label argenx can ultimately pursue. Competition in the FcRn inhibitor space from UCB’s rozanolixizumab and other emerging programs means argenx’s lead in this mechanism is real but not permanent. And at a market cap of approximately $56 billion on a single approved drug, the valuation demands continued execution at a pace that few biotechs sustain. For readers watching today’s abbreviated July 3rd session — markets close at 1 p.m. ET ahead of the holiday — argenx offers a story that is genuinely differentiated from the rotation out of AI hardware names and into software that has defined this week’s tape, with a specific near-term catalyst in Q3 that will tell you definitively whether the analysts carrying $1,000-plus price targets are right.